

# Central East Regional Cancer Program Key Performance Indicators – February 2026

Program	Indicator(s)	Central East - Regional Cancer Program	Denominator (N)	Previous Quarter	Denominator (N)	Percentage Change (+/-)	Target
OBSP	Participation – Q3 25/26	64.2% (50-74)	174,707	64.4%	174,424	-0.2%↓	>=65%
		28.0% (40-49)	76,871	25.6%	76,454	+2.4%↑	-
	Initial assessment procedure occurred within 3 weeks of abnormal screen date – Q2 25/26	78.0%	1,584	79.0%	1,774	-1.0%↓	>=90%
	Abnormal mammogram to dx without tissue biopsy within 5 weeks (40-74) – Q2 25/26	92.6%	1,378	95.1%	1,539	-2.5%↓	>=90%
	Abnormal mammogram to dx with tissue biopsy, within 7 weeks (40-74) - Q2 25/26	78.2%	206	78.9%	232	-0.7%↓	>=90%
High Risk OBSP MRI wait time, participants who returned within 15 months – Q3 25/26	80%	-	62%	-	+18%↑	>=85%	
CCC & GI Endoscopy	Participation – Q3 25/26	61.6%	353,228	62.2%	352,715	-0.6%↓	> 65%
	Abnormal fecal tests with no follow-up within six months – Q4 24/25	8.9%	507	8.9%	303	0%	<18%
	Abnormal fecal test result to referral wait time – Q3 25/26	20 days	-	19 days	-	+1 days↑	< 14 days
	Abnormal fecal test result to hospital colonoscopy wait time – Q3 25/26	51 days	-	55 days	-	-4 days↓	< =56 days
OCSP	Participation – Q3 25/26	61.6%	302,468	62.5%	302,655	-0.9%↓	>= 60%
	High grade cytology test or elevated risk screening result with no f/u within 6 months (25-69)- Q1 25/26	13.5%	347	18.5%	108	-5.0%↓	<=10%
	High grade cytology test or an elevated risk screening result to colposcopy wait times (25-69) – Q2 25/26	99 days	-	82 days	-	17 days↑	<=70 days

**Performance: Current Quarter vs Last Quarter**  
 ↓ = Decline from last quarter, positive change  
 ↓ = Decline from last quarter, off track  
 ↑ = Increase from last quarter, positive change  
 ↑ = Increase from last quarter, off track

**Performance: Current vs CCO Target**  
 Meeting/Exceeding Target  
 Approach Target (within 10%)  
 Not Meeting Target

Note. Quarterly data refresh is reflected in February, May, August, and November reports.